Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 3895-3903

  Silverman, Lewis R ^a   McKenzie, David R ^a   Peterson, Bercedis L ^a   Holland, James F ^a   Backstrom, Jay T ^a   Beach, C L ^a   Larson, Richard A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; BLOOD TRANSFUSION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; UTILIZATION REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOOD TRANSFUSION; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MULTICENTER STUDIES; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33748474416     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4346     Document Type: Article

References (12)

1. Silverman LR, Holland JF, Weinberg RS, et al: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7:21-29, 1993
2. Silverman LR, Holland JF, Demakos EP, et al: Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 68:A12, 1994 (abstr 46)
3. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
4. Kornblith AB, Herndon JE II, Silverman LR, et al: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III Trial: A Cancer and Leukemia Group B Study. J Clin Oncol 20:2441-2452, 2002
5. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
6. Germing U, Gattermann N, Strupp C, et al: Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 24:983-992, 2000
7. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
8. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
9. Pomeroy C, Oken MM, Rydell RE, et al: Infection in the myelodysplastic syndromes. Am J Med 90:338-344, 1991
10. de Witte T, Oosterveld M: Hematopoietic stem cell transplant strategies in patients with myelodysplastic syndrome and secondary acute myeloid leukemia: The role of reduced intensity conditioning regimens, in List AF, Vardiman J, Issa JPJ, et al (eds): Myelodysplastic Syndromes, Hematology: The American Society of Hematology Education Program Book. Washington, DC, American Society of Hematology, 2004, pp 308-313
11. Silverman LR, McKenzie DR, Peterson BL: Azacitidine prolongs survival and time to AML transformation in high risk myelodysplastic syndrome patients ≥ 65 years of age. Blood 106:709a, 2005 (abstr 2524)
12. Silverman LR, McKenzie DR, Peterson BL: Analysis of survival, AML transformation and transfusion independence in patients with high risk myelodysplastic syndromes receiving azacitidine determined using a prognostic model. Blood 106:708a, 2005 (abstr 2523)